Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Cincinnati Wellness Review.
Press releases published on June 30, 2025
HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy
GlobeNewswire
·
June 30, 2025
— Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy — — The only all-oral combination treatment option for these patients — — Consistent benefit regardless of …
Affidea Group selects b-rayZ as its preferred AI partner in breast imaging, marking strategic collaboration
GlobeNewswire
·
June 30, 2025
THE HAGUE, The Netherlands, June 30, 2025 (GLOBE NEWSWIRE) -- In a strategic move to improve patient outcomes in breast cancer, Affidea, a leading pan-European provider of community-based polyclinics, specialist services and advanced diagnostics, is proud …
Affidea-Gruppe wählt b-rayZ als bevorzugten KI-Partner für die Brustbildgebung und geht strategische Zusammenarbeit ein
GlobeNewswire
·
June 30, 2025
DEN HAAG, Niederlande, June 30, 2025 (GLOBE NEWSWIRE) -- Im Rahmen einer strategischen Maßnahme zur Verbesserung der Behandlungsergebnisse bei Brustkrebs gibt Affidea, ein führender paneuropäischer Betreiber von kommunalen Polikliniken sowie Anbieter von …
El Grupo Affidea elige a b-rayZ como colaborador preferente en IA para el diagnóstico mamario por imagen en una asociación estratégica
GlobeNewswire
·
June 30, 2025
LA HAYA, Países Bajos, June 30, 2025 (GLOBE NEWSWIRE) -- En una acción estratégica para mejorar los resultados de las pacientes con cáncer de mama, Affidea, proveedor paneuropeo líder en policlínicas comunitarias, servicios especializados y diagnóstico …
Le groupe Affidea choisit b-rayZ comme partenaire d’IA privilégié en imagerie mammaire, marquant ainsi le début d’une collaboration stratégique
GlobeNewswire
·
June 30, 2025
LA HAYE, Pays-Bas, 30 juin 2025 (GLOBE NEWSWIRE) -- Dans une démarche stratégique visant à améliorer les résultats des patientes atteintes d’un cancer du sein, Affidea, l’un des principaux prestataires paneuropéens de polycliniques de proximité, de …
Rakovina Therapeutics Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025
GlobeNewswire
·
June 30, 2025
VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)- …
AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors
GlobeNewswire
·
June 30, 2025
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE RENEGOTIATION OF LOAN REPAYMENT TERMS WITH ITS FINANCIAL CREDITORS AGREEMENT IN PRINCIPLE HAS BEEN REACHED ON A TWO-YEAR DEFERRAL OF REPAYMENT OF STATE-GUARANTEED LOANS SAVINGS OVER THE PERIOD WILL BE …
AB Science fait un point sur la renégociation des modalités de remboursement de ses emprunts avec ses créanciers financiers
GlobeNewswire
·
June 30, 2025
COMMUNIQUE DE PRESSE AB SCIENCE FAIT UN POINT SUR LA RENEGOCIATION DES MODALITES DE REMBOURSEMENT DE SES EMPRUNTS AVEC SES CREANCIERS FINANCIERS UN ACCORD DE PRINCIPE A ETE OBTENU SUR UN DECALAGE DE DEUX ANS DU REMBOURSEMENT DES PRETS GARANTIS PAR L’ETAT L …
Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial
GlobeNewswire
·
June 30, 2025
Results expected mid-August to mid-September 2025 New Drug Application (NDA) submission in the U.S. targeted for H1 2026 June 30, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international …
Nicox annonce que le dernier patient a terminé l’essai clinique de Phase 3 Denali sur NCX 470
GlobeNewswire
·
June 30, 2025
30 Juin 2025 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une société internationale spécialisée en ophtalmologie, annonce aujourd’hui que le dernier patient a terminé l’essai …
Press release: Availability of the Q2 2025 Aide mémoire
GlobeNewswire
·
June 30, 2025
Availability of the Q2 2025 Aide mémoire Paris, France – June 30, 2025. Sanofi announced today that its Q2 2025 Aide mémoire is available on the "Investors" page of the company's website: Second quarter 2025 (sanofi.com) As for each quarter, Sanofi …
Communiqué de presse : Mise en ligne du document «Q2 2025 Aide mémoire »
GlobeNewswire
·
June 30, 2025
Mise en ligne du document «Q2 2025 Aide mémoire » Paris, France, le 30 juin 2025. Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « Q2 2025 Aide mémoire ». Résultats du deuxième trimestre …
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy
GlobeNewswire
·
June 30, 2025
Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a potential first-in-class treatment Japanese Ministry of …
Communiqué de presse : Le riliprubart obtient la désignation de médicament orphelin au Japon pour la polyneuropathie inflammatoire démyélinisante chronique
GlobeNewswire
·
June 30, 2025
Le riliprubart obtient la désignation de médicament orphelin au Japon pour la polyneuropathie inflammatoire démyélinisante chronique Deux études de phase 3 sont actuellement en cours pour tester le riliprubart chez les personnes atteintes de PIDC comme …
argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
GlobeNewswire
·
June 30, 2025
Phase 1b study supports proof-of-concept in DOK7 congenital myasthenic syndromes Decision informed by favorable safety profile and consistent functional improvement over time across multiple efficacy measures Advancing ARGX-119 further validates strong …
Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders
GlobeNewswire
·
June 30, 2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland – June 30, 2025 – Addex Therapeutics (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological …
Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs
GlobeNewswire
·
June 30, 2025
Press Release Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs Geneva, Switzerland – June 30, 2025 – STALICLA SA, a Geneva-based clinical-stage biotech company pioneering …